Creathor Ventures becomes an investor in Haja Networks, joining Outlier Ventures and Polychain Capital. The funding round also features Berlin-based BigchainDB. Haja Networks is an ambitious start-up comprised of some of the early team behind OrbitDB and IPFS that is building two new and complementary open-source protocols to enable decentralised databases. … Read More
AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announced the expansion of its catalogue of kits for fully scalable multiplex protein analysis with the introduction of LUNARIS™ Human & Mouse 6-Plex T Cell Characterization Kits. The Kits are validated for quantitative analysis of soluble effector molecules secreted by distinct T cell populations that serve as biomarkers for specific population subsets. The kit enables translational research in areas including immune response biology, autoimmune disorders and cancer using murine and human samples. … Read More
Creathor Ventures announced today that it has, together with other investors, invested around EUR 10 million in a Series B investment round in Acousia Therapeutics GmbH. Acousia is a Tübingen/Germany-based leader in the discovery and development of novel therapies in inner ear related diseases and pathologies. Thebiotechnology company has developed drug candidates that will protect, repair and restore sensory hair cell function in patients suffering from hearing loss, caused by ototoxic drugs, normal aging process, noise and other conditions like sudden deafness. … Read More
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited (ASX:CSL; USOTC:CSLLY) today announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC’s proprietary CAP®Go technology. … Read More
The aim of the Nucleus Connecting Clinicians Open platform is to make rare genomic data accessible to health care professionals around the world. This platform provides them with the opportunity to share knowledge and phenotypes for rare disease patients with a Variant of Uncertain Significance (VUS) and Likely Pathogenic variants. … Read More
Swiss startups may look forward to larger sums in their seed financing rounds. Creathor Ventures with over EUR 230 million under management has joined the Swiss ICT Investor Club (SICTIC) as preferred co-investor. … Read More
Berlin/Bad Homburg v.d.H., January 30, 2017 – Creathor Ventures, together with Dieter von Holtzbrinck Ventures (DvH Ventures), Rheingau Founders, Rocket Internet and other investors, invests a significant seven-digit amount in HUMANOO, the Berlin-based provider of a digital health companion for employees and insured persons. HUMANOO intends to use the cash infusion to further expand the ... Read More
SIRION Biotech GmbH (“SIRION”), a world leader in virus based technology innovation and gene delivery expert providing custom services to commercial partners worldwide, announced today that it signed a two year development agreement with Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, to establish optimized AAV vectors for clinical applications in ocular gene therapy. … Read More
The number of furnished apartments in Germany has doubled within the last 4 years1. In order to enable easy renting and letting of these apartments online, Jan Hase and Arkadi Jampolski founded the property tech company Wunderflats in 2015. … Read More
Tenant apps are not only designed to improve tenant communication and achieve a corresponding boost in customer satisfaction, but to optimize workflows as well. Deloitte uses a model calculation to examine whether tenant apps can increase process efficiency in housing companies. The results, which are based anonymized usage data from Allthings, reveal time savings of up to 70%. … Read More
In March 2017 the Global Real Estate group of Credit Suisse Asset Management (Schweiz) AG decided to have its entire service portfolio from the LIVING SERVICES residential segment presented via the Allthings platform. Now, for the first time, an individually tailored service app will be implemented at four of their large business properties as well. Some 4,000 employees from companies in different regions of Switzerland will soon be able to use a multitude of digital services through the mobile application. … Read More
LUNARIS™ Mouse 12-Plex Th17 Kit comprises highly specific reagents for the quantitative analysis of soluble markers of Th17 cell biology Kit includes the primary Th17 related cytokines involved in autoimmune disorders, immune-mediated diseases as well as asthma, allergy, cancer, microbial defense and transplantation Launch marks a further step in establishing AYOXXA’s LUNARIS™ as the technology ... Read More
Mit der steigenden Digitalisierung der Medizin und neuen Konzepten wie Next Generation Sequenzierungstechnologien (NGS) und Artificial Intelligence (AI) beobachten wir das immer stärkere Zusammenwachsen von Software und Medizin. … Read More
Creathor Venture announced today that it is leading a financing round for Helsinki, Finland-based Blueprint Genetics. The company is an internationally successful provider of clinical genetic testing for the diagnosis of inherited diseases, leveraging a proprietary AI-enabled sequencing and interpretation platform. The start-up will receive a total of up to € 14 million from an international syndicate of investors. The financing round is led by new investors Creathor Venture and MedTech Innovation Partners (MTIP), while existing investors Inventure and Pontos Group are participating as well. … Read More
Phenex Pharmaceuticals AG (Phenex) today announced the achievement of a milestone in the collaboration with Janssen Biotech, Inc. (Janssen), which triggers a 6M US$ payment by Janssen. The milestone payment relates to a R&D collaboration between Phenex and Janssen, with a total potential value of 135 M USD, initiated in late 2012, to jointly discover RORgt inhibitors for the treatment of chronic inflammatory and autoimmune diseases. … Read More
Bad Homburg v.d.H., June 21st, 2017 – Creathor Venture, leading European venture capital firm, has promoted three of its long-time Investment Managers to Partners effective June 1st, 2017. Christian Leikert, Dr Christian Weiss and Christian Weniger complement Creathor’s management team, joining CEO Dr Gert Köhler and Managing Partners Karlheinz Schmelig and Cédric Köhler. With the ... Read More
Creathor Venture, a leading pan-European venture capital firm, together with a circle of experienced private investors from the real estate industry invest CHF 2.5 million in German-Swiss property tech company Allthings Technologies AG. … Read More
Jahr für Jahr werden Milliarden von Euro für Medikamente verschwendet, die keinen Effekt im Patienten haben. Doch seit Regulierungsbehörden die Entwicklung von Biomarkern zur Voraussetzung für die Zulassung neuer Medikamente machen (Companion Diagnostic) und Pharmafirmen sehr hohe Preise für ihre innovativsten Behandlungen in den Zielsegmenten durchsetzen können, gelingt der personalisierten Medizin Schritt für Schritt der Durchbruch. … Read More
Cédric Köhler, Managing Partner at Creathor Venture, a pan-European fund currently managing more than EUR 220 million, talks about their most successful investment so far and explains why Artificial Intelligence is 2017's buzzword in an interview with Susi Wallner from StartUs magazine. … Read More
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will collaborate with PlasmidFactory, the leading contract manufacturer and service provider for plasmid and minicircle DNA. … Read More
Creathor Venture, leading European venture capital firm in the high-tech space, announced today that they invest 1.5 million euros in Adaptive Simulations together with Estonian VC Karma Ventures. Adaptive Simulations is a spin-out of highly ranked tech-university KTH Royal Institute of Technology in Stockholm. … Read More
“For more than seven fund generations, our focus has been on tech and life sciences now as well as on the constantly increasing intersection of these two areas (e.g., digital health). There are not many VCs in Europe who can do both.” Creathor Venture’s Managing Partner Cédric Köhler talks about Creathor’s strategy in Berlin Valley’s series of short start-up portraits. … Read More
"The trade sale of Sividon to Myriad was the result of some kind of a marathon run consisting of years of negotiations and two M & A processes at the end of which the selling price was more than 100 percent above the first offer." Creathor Venture’s Managing Partner Karlheinz Schmelig writes about the long Sividon exit in Ernst & Young's annual German biotech report “Spot on Innovation!”. … Read More
"We see ourselves as a very active and dedicated partner. We have the know-how and a network of more than 30 years in the venture capital sector to support our portfolio companies," says Cédric Köhler, Managing Partner at Creathor Venture, in an interview with Deutsche-Startups.de. … Read More
Our Managing Partner Karlheinz Schmelig speaks about the changing dynamics in private equity, venture capital and Creathor's investment focus in an interview at Nordic Private Capital Day 2017 in Stockholm. … Read More
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications. … Read More
Berlin, February 21st, 2017 – R3Coms, the R3 – Reliable Realtime Radio Communications GmbH, has been selected by the jury of Startup Autobahn to take part in its Program #2 starting in March 2017. The decision was made after the participation of R3Coms in the Startup Autobahn Selection Day earlier this month. In this new ... Read More
Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development Cologne, Germany, February 09, 2017 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with ... Read More
Berlin/Bad Homburg v.d.H., January 23, 2017 – Creathor Venture, one of the leading European venture capital firms,together withVC FondsTechnologie Berlin, managed by IBB Beteiligungsgesellschaft, joins Berlin high-tech start-up R3 Communications as a partner. The investment is part of a pre-seriesA financing round. R3 Communications, founded in July 2015, develops ultra-reliable real-time communication systems that are ... Read More
(Martinsried, 12.01.2017) With the beginning of a new fiscal year SIRION Biotech GmbH, located at the Innovation and Start-Up Center for Biotechnology in Martinsried/Planegg near Munich, reports an annual growth of 140% to 4 million Euros in revenue, and profitability – just in time to celebrate its 10th year in the business. Decisive for this ... Read More
Ludwigshafen, Germany, January 06, 2017 – Phenex Pharmaceuticals AG (Phenex) yesterday announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674 targeting nonalcoholic steatohepatitis (NASH). GS-9674 is a novel, synthetic and nonsteroidal FXR agonist which was originally developed by ... Read More
Video interview with our Managing Partner Karlheinz Schmelig at Bio-Europe 2016 in Cologne. … Read More
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that is has submitted a Biologics Master File (BB-MF) for its human cell substrate CAP® to the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER). … Read More
Creathor Venture, one of the leading European Venture Capital firms, leads a new financing round in the rental car comparison site HAPPYCAR. Creathor Venture as well as the other existing investors HR Ventures, Capnamic Ventures, NWZ Digital and TruVenturo participated in the € 2.6 million financing round. … Read More
“Creathor’s investment confirms our strategy and the strong position iFunded has established as a real estate crowdinvesting platform,” says Michael Stephan, founder and CEO of iFunded.de. The platform allows both private and institutional investors to invest alongside real estate experts directly in the real estate projects of their choice. … Read More
Johannes-Philipp Berendes and Moritz Burmeister have been named new Managing Directors at Iconicfuture. With a lean and entrepreneurial business approach the two young managers aim to make the company more flexible and agile to operate successfully in the rapidly changing games market. … Read More
AYOXXA Biosystems GmbH, an international biotechnology company, and Märzhäuser Wetzlar GmbH & Co KG, a leading precision equipment manufacturer, joined forces to develop a dedicated benchtop device for the analysis of LUNARIS™ Multiplex assays. The AYOXXA Reader AR01 expands the technology platform to offer researchers a complete, flexible and user-friendly system for multiprotein analysis. The device was approved for routine laboratory work use in biomedical research. … Read More
Bad Homburg v.d.H., August 8th, 2016 – Creathor Venture, a leading pan-European Venture Capital firm, successfully sold its portfolio company News Republic, a worldwide leading global mobile news service operator for US$ 57 million. News Republic is an international mobile company focusing on changing the news ecosystem and the way people interact with the world ... Read More
Founded by Gert Köhler, the company has funded over 200 companies, and currently holds a portfolio of 35 startups. With close to 180 million in assets, the fund works with businesses in social media and networks, TV technology, shared economy, fintech, software, cloud computing, mobile health and personalised medicine, adjusting their lines of business depending on market trends. [...] … Read More
Creathor Venture, one of the leading European Venture Capital firms, leads a Series B financing round in CryoTherapeutics, the developer of a proprietary cryotherapy system for use in the treatment of coronary artery disease. The life science start-up CryoTherapeutics receives at total of € 5.2 million in the current Series B financing round from Creathor Venture as well as from the existing investors NRW.BANK, Peppermint CBF, High-Tech Gründerfonds (HTGF), Getz Brothers, Kreditanstalt für Wiederaufbau (KfW) and several renowned business angels. … Read More
A Zurich-based martech company, has opened its London office in Paddington and expanded its team to include Matthew Beck, Greg Carroll and Rahul Bathia. … Read More
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a strengthening of the Company reflective of its strategic progress. … Read More
A strategic collaboration between caprotec bioanalytics and Charles River has been established to offer their proprietary protein capture technology for phenotypic screening target deconvolution. … Read More
Sividon was a spin-off from Siemens, founded in July 2011 – and it was just sold to the American Myriad Genetics ($2.2Bn market cap) for €50M, even though the company raised only €5M over its lifetime. Philip Hemme (Co-Founder & CEO of Labiotech.eu) discussed this success story with Karlheinz Schmelig, partner of Sividon’s Lead investor Creathor Venture. ... Read More
Creathor Venture, one of the leading European Venture Capital firms, sells its shares in Sividon Diagnostics GmbH, the developer of the EndoPredict® test, to Myriad Genetics, Inc. (NASDAQ: MYGN). The financial terms for the transaction were €50 million incl. performance-based milestone payments for 100% of Sividon’s share capital. … Read More
Creathor Venture, one of the leading European Venture Capital firms, sells its stake in stylefruits GmbH, the European wide popular social commerce platform for fashion and living, to Ströer Content Group GmbH. … Read More
The Fintech company Knip reinforces its management team: Emily Kruse joined Knip AG as CFO in April 2016. … Read More
KNIP, a mobile digital Insurance manager, has been selected as one of the FinTech50 2016 companies. More than 1200 companies across Europe aimed for this award. The jury consists of the biggest names in FinTech. … Read More
The Swiss FinTech Award has been initiated by the Finanz und Wirtschaft Forum located in Zurich. Thursday night, the first Swiss FinTech Award has been granted to the two most promising and convincing Swiss Fintech-solutions Knip and Sentifi. … Read More
Inc. magazine ranked Viewster No. 10 on the 2016 Inc. 5000 list of fastest growing private companies in Europe and testifies Viewster a growth of 1,551% over the past three years. Average Growth Rate of Inc. 5000 Europe Companies is 226+% with Annual Revenue of €110 Billion. … Read More
AUSTIN, Texas–(BUSINESS WIRE)–Shopgate Inc., the leading SaaS retail app platform, adds Apple TV apps to their portfolio of shopping channels that already include iPhone, iPad and Android apps. Now, retailers can not only build apps designed for mobile devices, but also create retail apps designed for the recently launched Apple TV app store. With only ... Read More
The appointment of Sonja Glauert (37) as Head of Customer Relationship Management (CRM), previously Bosch eBike Service Manager, at the beginning of February brings an experienced eBike expert on board to enhance the COBI team. Christian Lortz (37) previously worked as Product Manager at SMART technologies and joined COBI as Senior Product Manager at the beginning of January. The engineering team has also been strengthened with the arrival of Ken Kölzer (29), former engineer at De’Longhi Braun Household, who joined COBI in February as Mechanical & Quality Engineer. … Read More
Phenex Pharmaceuticals AG (Phenex) today announced that the company will receive a milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A. for the initiation of a Phase 1 study for GS-9674, a novel, synthetic and non-steroidal FXR agonist, in non-alcoholic Steatohepatitis (NASH). In January 2015, Gilead acquired the Farnesoid X Receptor (FXR) program from Phenex, in a deal valued at 470 million US$. The FXR program is comprised of new small molecule therapeutics for the treatment of liver diseases, including NASH. … Read More
COBI, the developer of the first smart control centre for bikes, has completed another round of financing. The company has received almost €6.3 million from Munich Venture Partners and other investors like Meinders & Elstermann – International Print & Mediaservices. This brings the total investment raised by the company to 12 million Euros. Creathor Venture and Capnamic Ventures, investors from the previous funding round in April 2015, have also increased their investments. COBI will use the fresh capital for internationalization as well as the development of further products. … Read More
December 2015 – Creathor Venture invests in Happycar, one of Europe’s fastest growing price comparison portals for rental cars. With more than 250 cooperation partners, the Hamburg-based company has one of the largest networks of partners in its industry. … Read More
Hendrik Maat, CEO of zadego GmbH and its corporate branch easybooking, announces the opening of a long-planned new fourth office in Sopron, Hungary. This step has been taken earlier than planned due to a strong increase in customers in 2015 and is part of the very successful ongoing European rollout of the program. … Read More
Creathor Venture, one of the leading European Venture Capital firms, announces the partial exit of Mila AG, Berlin based sharing-economy platform to Swisscom, a leading Swiss ICT provider. The exit results in a substantial capital-gain for the Creathor-investors after a short holding-period. Mila (www.mila.com) was founded in 2013 as a spin-off of the software ... Read More
Gilles Raymond, News Republic’s founder and CEO, likes to use big numbers to describe his business: its app is available in 40 countries and 29 languages; news sourcing comes from 1500 separate deals with information providers, ranging from Reuters to The Guardian or Business Insider in the Western world, but also Hearst China, Sohu News (China), Baidu ... Read More
EndoPredict Spares Breast Cancer Patients Unnecessary Chemotherapy Cologne, November 12th, 2015 – The EndoPredict gene expression test developed and manufactured in Cologne now becomes available to breast cancer patients in the world’s most populous country: in China. This is made possible by a collaboration between the manufacturer, Sividon Diagnostics, and the Shanghai-based company Virchow Laboratories ... Read More
AYOXXA is Member of the International EYE-RISK Consortium LUNARIS™ multiplexing platform is applied in epidemiological studies for AMD Cologne, October 22nd, 2014 AYOXXA Biosystems GmbH, an international biotechnology company, is one of two industrial partners of EYE-RISK, a large biomedical consortium bringing together the expertise of ten renown scientific and clinical institutions and a ... Read More
CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies CEVEC’s CAP®Go to displace HEK293 and CHO cell lines in GMP manufacturing BioLamina to further grow its leading high ... Read More
Frank Ubags (CEO CEVEC Pharmaceuticals) is giving “insights from industry”. To see the full interview please click here: www.news-medical.net … Read More
Creathor Venture co-leads biggest Swiss Fintech financing round in Knip alongside Route 66 Ventures and QED with a total of USD 15.7 Million Digital insurance manager Knip disrupts the b2c insurance broker market Zurich, 26 October 2015 – With the Knip app, users can easily view and manage their portfolio of insurance policies ... Read More
Berlin based IT company Kyto, founded in 2013, secured a seven digit investment. Besides the participation of new investor Müller Medien and significant financial support via the Pro FIT program of Investitionsbank Berlin (IBB), existing investors Projects A Ventures, Creathor Ventures and Bauer Venture Partners contributed to the new investment. Kyto is an international software ... Read More
Agreement enables fully scalable, industrial lentivirus vector production Collaboration represents an important step in the roll-out of CEVEC’s strategy to position CAP®GT technology as the industrial standard for the production of lentiviral vectors for commercial gene therapy applications Cologne, Germany, September 17, 2015 CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made ... Read More
Cologne, September 14th, 2014 AYOXXA Biosystems GmbH, an international biotechnology company, announced that Dr. Gerald Möller has joined the company’s supervisory board as an independent board director and chairman of the board. With 40 years of experience in Pharma, Diagnostics and Biotech, Dr. Möller will guide AYOXXA’s strategic expansion from life science research into disease ... Read More
LUNARIS™ is AYOXXA’s unique technology platform combining the robustness and quality of classical immunoassays with the performance of modern bead-based methods delivered on a solid surface. LUNARIS™ BioChips enable researchers to perform simultaneous detection of multiple analytes in pg/mL concentrations, requiring minimal sample volumes. AYOXXA offers a flexible and scalable system for 32 to ... Read More
New and existing investors participated in this financing round CEVEC is setting new industry standards in glyco-optimized protein and gene therapy vector production with proprietary CAP®Go and CAP®GT technologies Cologne, Germany, July 22, 2015 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced ... Read More
Munich/Bad Homburg, June 10, 2015 Creathor Venture, one of the leading European Venture Capital firms, announces the exit of Danato GmbH, the popular German e-commerce market place for gifts, to Gruner + Jahr. Danato (www.danato.com) was founded in 2011 by Jörg Überla and has been growing rapidly since. Supported by Creathor and the other investors ... Read More
eHealth-pioneer from Berlin raises $ 2.5 million from Creathor Venture, Partech, Stephan Schambach, Heilemann Ventures and existing investor Atlantic Labs. The investment will fuel its US expansion. Founded in 2013 by Simon Bolz and Dr. Simon Lorenz, the startup aims to digitize the communication between doctors and patients. After entering German-speaking markets beginning 2014, Klara ... Read More
Digital Pioneers develop first smart system for bicycles Creathor Venture, Capnamic Ventures and Iris Capital invest in German bike startup Capital to drive production and establishment of distribution, marketing and customer service Frankfurt, April 15, 2015 – COBI, developer of the world’s smartest connected biking system, has completed one of the largest financing rounds ... Read More
US-based Clinipace Inc. acquires Accovion GmbH, Frankfurt Combined company has operations in 39 countries and employs nearly 1,000 staff Accovion CEO will head Clinipace’ European operations Heidelberg / Bad Homburg, April 13, 2015 – The independent Private Equity firms HeidelbergCapital and Creathor Venture together with former and current management and employees have sold their shares ... Read More
Memorado raises $3.3M Series A to become global leader in cognitive enhancement After growing to 1 million members in less than 6 months, Memorado now has over 3.5 million members just a year after launch. Series A funding led by Creathor Venture and Global Founders Capital with participation from existing investors Sunstone Capital and ... Read More
Bad Homburg, Germany and Boulder, Colorado (USA). Creathor has invested into Sinopsys Surgical, a clinical stage medical device company in Boulder, Colorado. Sinopsys has developed a stent device called the Sinopsys Lacrimal Stent. The lead indication for the stent is chronic rhinosinusitis with additional use in epiphora and potential in allergic rhinitis. Participants in this ... Read More
For today’s article at “Rhein-Main-Startups.de” Karlheinz Schmelig (Partner at Creathor Venture) and Dr. Maria Deeg were talking about trends, developments and founding location Rhein-Main. Click here to see whole interview! … Read More
News Republic won “Best Mobile Media and Publishing App” at Mobile World Congress 2015 in Barcelona. The award was presented by John Cleese on behalf of MWC’s 300 judges. Judges Comments: “Genuinely a step forward in terms of curation, intuitive design and connecting editorial interests for consumers. A pleasure to use.” For more information ... Read More
As part of the EU RESPONSIFY research project, immune markers in tumours, which not only affect the prognosis of a breast cancer patient but also predict the response to certain treatments, were identified for the first time. In patients with HER2-positive or triple negative breast cancer (TNBC) in particular, the results of the research point the way ahead. These types of breast carcinomas are characterised by an aggressive progression of the disease, meaning that the development of new treatment strategies is particularly necessary for these Patient Groups. ...Read More
Testdroid Professional Services – A Dedicated Specialist for Automating Your App Testing Dear Testdroiders, As you might know, we’ve offered professional services for creating test scripts and integrating all Testdroid products into your continuous integration environments, build systems, various different tools and other scripts. Today, we’re launching a new service that will bring you even ... Read More
Deconstructing Continuous Quality Process for Mobile App Development Dear Testdroiders, Mobile app users and gamers are more demanding than ever before. According to McKinsey and their analysts, the application related revenues have reached $25 billion already in 2013 and are on the way to reach more than $70 billion by 2017. In this study, the ... Read More
Insiteo, the leader in indoor location and proximity marketing deployed its services in Toulouse-Blagnac Airport to empower the new mobile application released this month. The application, available for iPhone and Android devices, has been specifically designed for frequent flyers with an innovative “find-my-car” feature. Indeed, the parking lot is automatically stored in the application thanks ... Read More
Validation of new protein multiplexing technology platform in the ophthalmic domain Cologne and Singapore 03. February 2015 AYOXXA, an international biotech company with headquarters in Cologne, has signed an agreement with the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s ... Read More
Creathor’s portfolio company Phenex Pharmaceuticals announces acquisition of its development program for non-alcoholoic steatohepatitis (NASH) and other liver diseases by Gilead Sciences, Inc., for up to $470m January 7, 2015 – Bad Homburg, Ludwigshafen/Heidelberg, Foster City, CA Gilead Sciences, Inc. (Nasdaq: GILD) and Phenex Pharmaceuticals AG, a Creathor portfolio company, today announced the signing of ... Read More
Frankfurt / Eschborn, December 1, 2014 Accovion, a leading independent European full-service Contract Research Organization, headquartered in Frankfurt (Eschborn), Germany, announced today the establishement of a new subsidiary in Lyon, France, as it continues its expansion across Europe. Together with offices in Italy, Poland, Russia, Romania, Spain, Czech Republic and United Kingdom, Accovion is ... Read More
Bad Homburg / Frankfurt am Main, June 2011. The international venture capital company Creathor Venture has successfully sold its shares in online marketing company Jaron GmbH. The digital media group UDG is an agency network for digital communication in Germany. The parties have agreed not to disclose any details of the transaction. With Creathor Venture ... Read More
The German Venture Capital company Creathor Venture has successfully sold its stake in Swiss scheduling platform Doodle AG. As part of this exit, the Swiss media company Tamedia AG acquired 49% of Doodle’s shares. Terms of this deal will not be disclosed. … Read More